Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis

Support Care Cancer. 2023 Mar 20;31(4):223. doi: 10.1007/s00520-023-07686-7.

Abstract

Background: Radiotherapy-induced oral mucositis (RIOM) and chemotherapy-induced oral mucositis (CIOM) are common complications in cancer patients, leading to negative clinical manifestations, reduced quality of life, and unsatisfactory treatment outcomes.

Objective: The present study aimed to identify potential molecular mechanisms and candidate drugs by data mining.

Methods: We obtained a preliminary list of genes associated with RIOM and CIOM. In-depth information on these genes was explored by functional and enrichment analyses. Then, the drug-gene interaction database was used to determine the interaction of the final enriched gene list with known drugs and analyze the drug candidates.

Results and conclusion: This study identified 21 hub genes that may play an important role in RIOM and CIOM, respectively. Through our data mining, bioinformatics survey, and candidate drug selection, TNF, IL-6, and TLR9 could play an important role in disease progression and treatment. In addition, eight candidate drugs (olokizumab, chloroquine, hydroxychloroquine, adalimumab, etanercept, golimumab, infliximab, and thalidomide) were selected by the drug-gene interaction literature search additionally, as candidates for treating RIOM and CIOM.

Keywords: Chemotherapy-induced oral mucositis; Data mining; Inflammatory reaction; Radiotherapy-induced oral mucositis.

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Humans
  • Mucositis* / chemically induced
  • Neoplasms* / drug therapy
  • Quality of Life
  • Stomatitis* / chemically induced
  • Stomatitis* / drug therapy

Substances

  • Antineoplastic Agents